[Insilico Intelligent: Announced preliminary positive data from the first-in-human Phase I clinical trial of ISM6331] On October 27, Insilico Intelligent announced on the Hong Kong Stock Exchange that the company recently released preliminary positive data from the first-in-human Phase I clinical trial of ISM6331 in a rapid oral presentation at the 2026 European Society for Medical Oncology (ESMO) Annual Meeting. ISM6331 is an investigational oral pan-TEAD inhibitor designed and powered by the Chemistry42 generative AI platform. As of the data cutoff date of August 14, 2026, among mesothelioma subjects with evaluable efficacy, the objective response rate (ORR) in the once-daily 130 mg dose group reached 40%, and in the 30-130 mg dose range, the disease control rate (DCR) at the first tumor assessment reached 68.2%.